Takeda, Wave Life Sciences revise their $230M R&D collaboration, dropping discovery work
Three years after Takeda paid a hefty down payment on a research collab with Wave Life Sciences, the two partners have revised the pact.
The Cambridge biotech announced a revision to its deal with Takeda yesterday — ending their alliance on discovery work. As part of the amendment, Takeda will pay Wave more than $22 million for research and preclinical expenses from the collaboration.
Back in 2018, Cambridge, MA-based Wave entered a mega-deal with Takeda. The deal was two-fold: Wave gave Takeda the option to co-develop and co-commercialize programs in Huntington’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and spinocerebellar ataxia type 3. Takeda also had the right to license several of Wave’s preclinical programs targeting CNS disorders, including Alzheimer’s and Parkinson’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.